Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361292 | 0.78 | CYP3A4 (0.42) | KDM4ENPSR1PKMCYP3A4CYP3A5 | |
| SCHEMBL3362187 | 0.78 | CYP3A4 (0.56) | KDM4ECYP3A4CYP3A5NFE2L2FNTA | |
| SCHEMBL3294357 | 0.73 | PSEN1 (0.46) | KDM4ENPSR1PKMCYP3A4CYP3A5 | |
| SCHEMBL2913321 | 0.73 | PSEN1 (0.46) | KDM4ENPSR1PKMCYP3A4CYP3A5 | |
| SCHEMBL3297981 | 0.72 | CYP2D6 (0.37) | CYP3A4CYP3A5CHRM2HTR1AADRA2A | |
| SCHEMBL3294293 | 0.68 | DRD3 (0.39) | KDM4ENPSR1CYP3A4CYP3A5CHRM2 | |
| SCHEMBL3357725 | 0.66 | ALDH1A1 (0.40) | CYP3A4CYP3A5SLC6A2SLC6A4HRH3 | |
| SCHEMBL7652781 | 0.65 | CYP3A4 (0.38) | CYP3A4CHRM2ADRA2ACHRM1DRD1 | |
| SCHEMBL1500553 | 0.65 | CYP2D6 (0.53) | KDM4ECYP3A4CHRM2HTR1AADRA2A | |
| SCHEMBL4029679 | 0.64 | GPX4 (0.35) | CYP3A4CYP3A5CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741316-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2010-06-22 | — | — | US | disclosed |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6872717-B2 | Pharmacological uses of azetidine derivatives | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ACHARD DANIEL (FR) | 2003-03-20 | — | — | US | disclosed |
| US-6479479-B2 | 1-DIARYLMETHYL-4-ALKYL OR ALKYLSULFONYLALKYL-AZETIDINES; CANNABINOID RECEPTOR ANTAGONISTS; NERVOUS SYSTEM DISORDERS (CNS); CARDIOVASCULAR AND GLANDULAR DISORDERS; DRUG ABUSE; PSYCHOLOGICAL DISORDERS; | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | KDM4E 1190/4885NPSR1 1896/4885PKM 3552/4885 |
| US-20030055033-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | KDM4E 1190/4885NPSR1 1896/4885PKM 3552/4885 |
| US-20050130953-A1 | Pharmacological uses of azetidine derivatives | CHRM2, ACHE, DRD2 | KDM4E 2841/4885NPSR1 270/4885PKM 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.